Hualan Biological Engineering released its 2026 interim report. First-half net profit attributable to the parent was 383 million yuan, down 25.7% year on year. Operating revenue was 1.57 billion yuan, down 12.9% year on year. Net profit attributable to the parent after deducting non-recurring items was 342 million yuan, down 29.4% year on year. Net operating cash flow was 343 million yuan, up 48.7% year on year. Earnings per share were 0.21 yuan. In the second quarter, operating revenue was 805 million yuan, down 13.5% year on year, and net profit attributable to the parent was 153 million yuan, down 24.5% year on year. As of the end of the second quarter, total assets were 14.548 billion yuan, down 4.7% from the end of the previous year, and net assets attributable to the parent were 10.972 billion yuan, down 4.6% from the end of the previous year. The company said both its blood products and vaccine businesses faced significant changes. Influenza vaccine sales fell 90.86% from the same period last year, but plasma collection volume in the first half rose 16.55% from a year earlier.
Hualan Biological EngineeringIncFirst-half net profit fell 25.7% and revenue dropped 12.9%, with influenza vaccine sales down 90.86%.
